Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Microbiol. 2013 Jun;21(6):277-85. doi: 10.1016/j.tim.2013.02.005. Epub 2013 Mar 18.

Reactivation of latent HIV by histone deacetylase inhibitors.

Author information

1
Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA 94158, USA.

Abstract

Latent HIV persists in CD4(+) T cells in infected patients under antiretroviral therapy (ART). Latency is associated with transcriptional silencing of the integrated provirus and driven, at least in part, by histone deacetylases (HDACs), a family of chromatin-associated proteins that regulate histone acetylation and the accessibility of DNA to transcription factors. Remarkably, inhibition of HDACs is sufficient to reactivate a fraction of latent HIV in a variety of experimental systems. This basic observation led to the shock and kill idea that forcing the transcriptional activation of HIV might lead to virus expression, to virus- or host-induced cell death of the reactivated cells, and to the eradication of the pool of latently infected cells. Such intervention might possibly lead to a cure for HIV-infected patients. Here, we review the basic biology of HDACs and their inhibitors, the role of HDACs in HIV latency, and recent efforts to use HDAC inhibitors to reactivate latent HIV in vitro and in vivo.

PMID:
23517573
PMCID:
PMC3685471
DOI:
10.1016/j.tim.2013.02.005
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center